Inhaled epoprostenol utilization pattern after implementation of an administration policy

Area of Science:

• Pulmonary Medicine
• Critical Care

Background:

• Epoprostenol is a pulmonary vasodilator used to decrease pulmonary artery pressure.
• Inhaled epoprostenol improves ventilation-perfusion matching and oxygenation.
• It is a treatment for acute respiratory distress syndrome (ARDS) and pulmonary arterial hypertension.

Purpose of the Study:

• To analyze inhaled epoprostenol utilization in ARDS patients post-policy implementation.
• To compare clinical outcomes and physiologic changes between responders and non-responders.
• To evaluate compliance with the standardized clinical practice policy.

Main Methods:

• Retrospective analysis of 30 patients (14 ARDS, 16 non-ARDS) meeting inclusion criteria.
• Epoprostenol was administered as a second rescue agent in ARDS patients.
• Comparison of pre- and post-utilization oxygenation, clinical outcomes, and policy compliance.

Main Results:

• Epoprostenol significantly improved oxygenation in ARDS patients (PaO2/FiO2 ratio 70 vs 140, P=0.04).
• 71% of ARDS patients and 56% of non-ARDS patients responded to epoprostenol.
• No significant outcome differences were observed between responders and non-responders.
• Policy compliance was achieved in 80% of patients.

Conclusions:

• Inhaled epoprostenol effectively improves oxygenation in ARDS patients.
• Standardized policy implementation demonstrated good compliance.
• Further research may clarify the impact of epoprostenol on clinical outcomes in ARDS.